Dr. Siamak Daneshmand, MD

Dr. Daneshmand practices at Urology - Nch Urology - HOPD in Los Angeles, California.

Dr. Daneshmand's NPI, 1174546568, was assigned on July 26, 2006. Dr. Daneshmand graduated from UC Davis School of Medicine in 1996. Dr. Daneshmand holds California license A63444.

Dr. Daneshmand's primary practice is Urology - Nch Urology - HOPD, at 1516 San Pablo St, Los Angeles, CA 90033.

Dr. Daneshmand's primary practice is Urology - Nch Urology - HOPD in Los Angeles, California. Dr. Daneshmand is also affiliated with Cedars-Sinai Medical Center. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Daneshmand to 2 more hospitals, 2 hospital outpatient departments, 1 group practice or clinic, 1 home health agency and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Daneshmand practices, 9 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Daneshmand's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Daneshmand is board certified in urology by the American Board of Urology. Dmand AI has Dr. Daneshmand's licenses on file in 2 states: California and Oregon.

Dmand AI lists bladder removal, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stones and prostate cancer among the conditions Dr. Daneshmand treats.

CMS data shows 1,168 Medicare services from Dr. Daneshmand across 12 procedure codes in 2024, for 570 Medicare patients. Medicare paid $130,720 for them.

CMS counts 570 Medicare patients who saw Dr. Daneshmand in 2024. The largest group is 75 to 84, with 241 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 1.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Daneshmand's median patient age at 74, with 20% women.

In 2024, Dr. Daneshmand wrote 135 Medicare Part D claims for 45 patients. 76% of them were for generic drugs. CMS names the drug for 110 of them, across 6 drugs with 11 or more claims each, at $20,877 in total drug cost. In 2023, CMS named 44 claims across 2 drugs.

Dr. Daneshmand accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Daneshmand as offering telehealth. CMS counts 23 procedures of prostate resection by Dr. Daneshmand, more than 85% of the clinicians it reports for that procedure.

Hernia repair (minimally invasive): 1 to 10 procedures (CMS shows small counts as a range)

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 19 papers to Dr. Daneshmand, published from 2003 to 2025. 2016 was the busiest year, with 4. Dr. Daneshmand's most frequent co-authors are Jay Shah, MD, Peter C. Black, MD and Gaetano Ciancio, MBA, MD.

Dmand AI links Dr. Daneshmand to 16 clinical trials, 5 of them phase 3 studies. 6 are still active or recruiting. Conditions studied include Urinary Bladder Neoplasms, Urinary Bladder Diseases and Non-Muscle Invasive Bladder Neoplasms. University of Southern California sponsors the most, 6.

CMS Open Payments shows 366 general payments to Dr. Daneshmand from 36 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 72% of the total. Photocure Inc paid the most, $168,222. It also lists 1 research payment totaling $2,327 in 2021.

Dmand AI lists 22 awards for Dr. Daneshmand, most recently America's Top Doctors in 2017.

Dr. Daneshmand graduated from UC Davis School of Medicine in 1996. Dr. Daneshmand is a member of AUA.

Dr. Daneshmand is in network with 7 carriers, including Blue Cross Blue Shield of Michigan, Blue Cross Blue Shield of Massachusetts and HCSC. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.